Bob Curtis

Bob has an extensive background and network in the medical technology field from his 30+year career as a senior executive,, founder, and operating manager of multiple life science technology startups, and as a venture capital accelerator/ incubator manager and investor. He was the early CEO of Aerogen, Inc., an early-stage metered dose inhaler company, and has also served as CEO and/or Board member of one (1) public and nine (9) venture capital financed start-ups. He was the co-founder of two successful San Francisco Bay Area medical technology venture capital accelerator/incubators that enabled the startup of 6 companies over a 5 year period. Previously, as CEO of a $200 Million medical device subsidiary of Pfizer Inc., (PFE) he had responsibility for multiple buy-side transactions, including 3 companies that he combined to create the Schneider angioplasty subsidiary of Pfizer, which was sold to Boston Scientific for $2.2 Billion. Bob is an inventor orco-inventor of 13 issued US and foreign patents and holds BS Chemical Engineering and MS Mechanical/Bioengineering degrees, from the University of California, Berkeley.